Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

New Targets in Non-Small Cell Lung Cancer.

Hematology/oncology clinics of North America - 1 Feb 2017

Park Soo J, More Soham, Murtuza Ayesha, Woodward Brian D, Husain Hatim

Abstract excerpt

With the implementation of genomic technologies into clinical practice, we have examples of the predictive benefit of targeted therapy for oncogene-addicted cancer and identified molecular dependencies in non-small cell lung cancer. The clinical success of tyrosine kinase inhibitors against epidermal growth factor receptor and anaplastic lymphoma kinase activation has shifted treatment emphasize the separation of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Antineoplastic Agents
Share to Drug Delivery Systems

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to NTRK1 gene

Share to ROS1 gene

Share to Lung Neoplasms

Share to Mutation

Share to Neoplasm Proteins

Source

Identifiers

PMID: 27912827
DOI: 10.1016/j.hoc.2016.08.010

Genes

BRAF
KRAS
MET
NTRK1
RET
ROS1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

New Targets in Non-Small Cell Lung Cancer.PMID 27912827Read ↗

Targeted Therapy for Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations.Semantic proximity Read ↗

New Targets in Lung Cancer (Excluding EGFR, ALK, ROS1).Semantic proximity Read ↗

Current Landscape of Targeted Therapy in Lung Cancer.Semantic proximity Read ↗

Novel Emerging Molecular Targets in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Molecular Targets Beyond the Big 3.Semantic proximity Read ↗

Treatment of Patients With Non-Small-Cell Lung Cancer Harboring Rare Oncogenic Mutations.Semantic proximity Read ↗

Targeted Therapy for Non-Small Cell Lung Cancer: First Line and Beyond.Semantic proximity Read ↗

Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma.Semantic proximity Read ↗

Targeting molecular alterations in non-small-cell lung cancer: what's next?Semantic proximity Read ↗

Emerging targeted therapies in non-small cell lung cancer.Semantic proximity Read ↗

Management and future directions in non-small cell lung cancer with known activating mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.